Trueblood Wealth Management LLC Invests $261,000 in IQVIA Holdings Inc. (NYSE:IQV)

Trueblood Wealth Management LLC purchased a new position in IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,128 shares of the medical research company’s stock, valued at approximately $261,000.

Several other institutional investors also recently bought and sold shares of IQV. Norges Bank acquired a new position in shares of IQVIA in the 4th quarter valued at about $408,232,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in IQVIA by 1,852.5% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,066,764 shares of the medical research company’s stock worth $423,466,000 after acquiring an additional 1,960,914 shares during the period. Alliancebernstein L.P. grew its position in IQVIA by 19.1% in the second quarter. Alliancebernstein L.P. now owns 5,942,761 shares of the medical research company’s stock worth $1,335,754,000 after acquiring an additional 952,850 shares during the period. AMF Tjanstepension AB purchased a new position in IQVIA in the third quarter worth approximately $148,096,000. Finally, Eagle Asset Management Inc. acquired a new position in IQVIA during the third quarter worth $102,982,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now directly owns 796,752 shares in the company, valued at $199,610,278.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other IQVIA news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the sale, the insider now owns 796,752 shares in the company, valued at approximately $199,610,278.56. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Eric Sherbet sold 1,000 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $241.50, for a total transaction of $241,500.00. Following the transaction, the insider now owns 20,836 shares in the company, valued at approximately $5,031,894. The disclosure for this sale can be found here. In the last 90 days, insiders sold 41,285 shares of company stock worth $10,331,003. Insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of research reports. Leerink Partnrs restated an “outperform” rating on shares of IQVIA in a research note on Monday, February 26th. Guggenheim cut IQVIA from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. Evercore ISI increased their price objective on IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a research note on Thursday, February 15th. UBS Group increased their price objective on IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a research note on Thursday, February 15th. Finally, Truist Financial increased their price objective on IQVIA from $286.00 to $297.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $256.80.

IQVIA Stock Up 0.1 %

Shares of IQVIA stock opened at $252.89 on Friday. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12. The stock has a market cap of $45.90 billion, a price-to-earnings ratio of 34.69, a price-to-earnings-growth ratio of 2.44 and a beta of 1.51. The company has a fifty day moving average price of $236.43 and a 200 day moving average price of $217.77.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 EPS for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. The firm had revenue of $3.87 billion for the quarter, compared to analyst estimates of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. The firm’s revenue was up 3.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.54 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.